Novel drugs for treating cGvHD: Phase I results of axatilimab for heavily pretreated patients

Second line or further lines of therapy represent an unmet need in treating patients with chronic...

Novel drugs for treating cGvHD: preliminary phase I/II results for baricitinib

Chronic graft-versus-host disease (cGvHD) is associated with organ function impairment, shorter survival, and immune...

REACH3 study: Should ruxolitinib become SoC for steroid-dependent or refractory chronic GvHD?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to...

How does stem cell source impact GvHD?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We...

Novel drugs for treating cGvHD: Phase I results of axatilimab for heavily pretreated patients

Second line or further lines of therapy represent an unmet need in treating patients with chronic...

Novel drugs for treating cGvHD: preliminary phase I/II results for baricitinib

Chronic graft-versus-host disease (cGvHD) is associated with organ function impairment, shorter survival, and immune...

How does stem cell source impact GvHD?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We...

High- vs low-dose antithymocyte globulin for pediatric patients with leukemia undergoing allo-PBSCT

A study by Hyun Mi Kang et al. investigated the effects of different ATG dosages on the overall...

Editorial theme | Latest advances in microbiome interventions

This article summarizes talks and posters presented at the virtual 46th Annual Meeting of the European Society for Blood and Marrow...

The impact of JAK inhibitor use on HSCT outcome in patients with MPN

Barabanshikova and colleagues analyzed outcomes of patients with MPN undergoing allo-HSCT with or without prior JAK inhibitor...

KD025 for chronic GvHD: an update

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) two posters were presented by Madan Jagasia on KD025 (belumosudil).

How should antibiotics be administered in transplant patients to reduce GvHD?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to...